Charlottte (Talk | contribs) |
Charlottte (Talk | contribs) |
||
Line 430: | Line 430: | ||
<body> | <body> | ||
<div class="nav"> | <div class="nav"> | ||
− | <li><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li> | + | <li style="width:10%;"><img src="https://static.igem.org/mediawiki/parts/3/3b/Wiki_logo.png" alt="logo" class="logo1"></li> |
<li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li> | <li><img src="https://static.igem.org/mediawiki/parts/6/6a/Wiki_4.png" alt="logo" class="logo2"></li> | ||
− | <li><a href="../ | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B">Home</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Project</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Overview">Overview</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Propoptosis">Apoptosis Induction</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protumor">Tumor specific promoter</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
− | <li><a href="">Achievements</a> | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Achievements</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href="">Results</a></li> | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Results">Results</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Parts">Parts</a></li> |
+ | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Judging">Judging</a></li> | ||
</ul> | </ul> | ||
</li> | </li> | ||
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Modeling">Modeling</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Apoptosis">Apoptosis</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Crispri">CRISPRi/a</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
− | <li><a href="">Notebook</a> | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Notebook</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Protocol">Protocol</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Safety">Safety</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Human Practice</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/Gold">Overview</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP1">Project Design</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP2">Public Outreach</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/HP/HP3">Hospice Care</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
− | <li><a href="">Lab</a> | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Lab</a> |
− | <ul> | + | <ul class="ultop"> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Team">Team</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Collaborations">Collaborations</a></li> |
− | <li><a href=" | + | <li><a href="https://2016.igem.org/Team:SCUT-China_B/Attributions">Attributions</a></li> |
</ul> | </ul> | ||
</li> | </li> |
Revision as of 18:00, 28 November 2016
PARTNAME | PARTNUMBER |
---|---|
sgRNA-generator | BBa_K2080000 |
bax-sgRNA-1 | BBa_K2080001 |
bax-sgRNA-2 | BBa_K2080002 |
bax-sgRNA-3 | BBa_K2080003 |
bcl-2-sgRNA-1 | BBa_K2080004 |
bcl-2-sgRNA-2 | BBa_K2080005 |
bcl-2-sgRNA-3 | BBa_K2080006 |
bcl-2-sgRNA-4 | BBa_K2080007 |